The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Improving outcomes for hemophilia patients through the implementation of gene therapies
In recent years, notable progress in gene therapy for hemophilia has led to FDA approvals. In this video, Evelien Krumb, MD, UCLouvain Saint-Luc, Brussels, Belgium, discusses how gene therapy can potentially eliminate bleeding episodes, avoiding the need for regular treatments and alleviating the psychological burden of living with hemophilia. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Swedish Orphan Biovitrum (Sobi), CSL Behring
Honoraria: BioMarin
